

depend on time, eg, recurrence of a specific event (such as heart failure or myocardial infarction). The best approach to take into account for these kinds of variables in cardiovascular diseases is multistate models, while other methods have some limitations for time-dependent variables. Despite the importance of cardiovascular diseases and, given the fact that by 2030, the leading causes of death in the high-, middle- and low-income countries will be cardiovascular diseases,² there are few studies about the application of multistate models in cardiovascular diseases. Two examples are Ieva et al⁷ and Zhang et al.⁸

To sum up, multistate models can lead to early detection, improved disease prognosis, and reduced cost of the disease for families and governments, which are the main concerns of ministries of health and other policymakers. Therefore, it is suggested that this model be more focused on by policymakers to save financial resources and reduce the costs of the health system.

Morteza Hajhosseini,^{a,*} Toba Kazemi,^a and Javad Faradmal^b

^aAtherosclerosis and Coronary Artery Research Center, Birjand University of Medical Sciences, Birjand, Iran

^bDepartment of Biostatistics, Modeling of Noncommunicable Diseases Research Center, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran

* Corresponding author:

E-mail address: mortezahaji87@gmail.com (M. Hajhosseini).

Available online 25 May 2016

REFERENCES

1. Alwan A, MacLean DR, Riley LM, D'Espaignet ET, Mathers CD, Stevens GA, et al. Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. Lancet. 2010;376:1861-8.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
3. Pouche M, Ruidavets JB, Ferrieres J, Iliou MC, Douard H, Lorgis L, et al. Cardiac rehabilitation and 5-year mortality after acute coronary syndromes: The 2005 French FAST-MI study. Arch Cardiovasc Dis. 2016;109:178-87.
4. Forouzanfar MH, Sepanlou SG, Shahraz S, Dicker D, Naghavi P, Pourmalek F, et al. Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. Arch Iran Med. 2014;17:304-20.
5. Kazemi T, Nik M. "World heart day 2014", significance of cardiovascular diseases in East of Iran. J Res Med Sci. 2015;20:423.
6. Schmoor C, Schumacher M, Finke J, Beyermann J. Competing risks and multi-state models. Clin Cancer Res. 2013;19:12-21.
7. Ieva F, Jackson CH, Sharples LD. Multi-state modelling of repeated hospitalisation and death in patients with heart failure: The use of large administrative databases in clinical epidemiology. Stat Methods Med Res. 2015 Mar 26. pii: 0962280215578777. [Epub ahead of print].
8. Zhang X, Li Q, Rogatko A, Tighiouart M, Hardison RM, Brooks MM, et al. Analysis of the bypass angioplasty revascularization investigation trial using a multistate model of clinical outcomes. Am J Cardiol. 2015;115:1073-9.

<http://dx.doi.org/10.1016/j.rec.2016.04.009>

About the Micra Transcatheter Pacing System



Acerca del sistema de marcapasos transcatéter Micra

To the Editor,

We read in detail the interesting article by Pachón et al¹ on implantation of the Micra transcatheter pacing system. Due to its characteristics, this model could undoubtedly be extremely useful in certain patients.² However, it has certain limitations. Regarding the series of 10 patients presented, we would like to make several observations:

Of the 10 patients, 2 (patients 5 and 8) were in sinus rhythm prior to implantation; usually, implantation with a DDD pacemaker would be indicated in this situation. With right ventricular pacing only, atrial fibrillation is likely to develop in the medium- to long-term. This is particularly likely in the case of the patient with a pacing percentage of more than 20%, as measured after implantation. Aside from the clinical deterioration that could result from the loss of atrioventricular synchrony, the patient would require anticoagulation. In the case of the other patient with a baseline sinus rhythm, the R wave amplitude was only 4.7 mV after the first implantation, whereas the manufacturer's recommendation³ is ≥ 5 mV.

Patients 1 and 2 have a pacing threshold of 0.24 ms higher than the manufacturer's recommendation in the technical specifications³ (1 mV).

Regarding the patient with a QRS of 140 ms and erratic control of atrial fibrillation (patient 4), it is possible that at follow-up she will require a change to cardiac resynchronization therapy (provided the clinical profile indicates and allows this). With this system, such a

change would not be feasible and could even hamper implantation of new electro-catheters in the right ventricle.

In light of these points, this seems to be an interesting and novel pacing system, but with some limitations, especially for patients who are in sinus rhythm or who require a change to cardiac resynchronization at follow-up.

Ángel Morales Martínez de Tejada* and Javier Elduayen Gragera

Servicio de Cardiología, Hospital Regional Universitario Infanta Cristina, Badajoz, Spain

* Corresponding author:

E-mail address: hispano0@yahoo.es
(Á. Morales Martínez de Tejada).

Available online 25 May 2016

REFERENCES

1. Pachón M, Puchol A, Akerström F, Rodríguez-Padial L, Arias MA. Implante de marcapasos sin cables transcatéter Micra: experiencia inicial en un centro español. Rev Esp Cardiol. 2016;69:346-9.
2. Miller MA, Neuzil P, Dukkipati SR, Reddy VY. Leadless cardiac pacemakers: back to the future. J Am Coll Cardiol. 2015;66:1179-89.
3. Reynolds D, Duray GZ, Omar R, Soejima K, Neuzil P, Zhang S, et al. A leadless intracardiac transcatheter pacing system. N Engl J Med. 2016;374:533-41.

SEE RELATED ARTICLES:

- <http://dx.doi.org/10.1016/j.rec.2015.11.020>
<http://dx.doi.org/10.1016/j.rec.2016.04.016>

<http://dx.doi.org/10.1016/j.rec.2016.04.011>